Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a promising clinical-stage biopharmaceutical company that has shown potential in developing circuit-specific pharmacotherapies for central nervous system disorders through its discovery platform. The company has a strong cash position and upcoming partnerships with the FDA, indicating a clear path forward for its product candidate, ML-007C-MA, in both schizophrenia and Alzheimer's disease psychosis. With potential differentiations in dosing convenience and timepoints for measuring primary endpoints, and a favorable safety profile compared to competitors, MapLight Therapeutics has solid prospects for success in the market.

Bears say

MapLight Therapeutics is facing challenges with their ML-007C-MA product candidate, as the once-daily dosing regimen has shown only mild improvement over placebo on the primary endpoint and may not be as potent as originally expected. Additionally, the company has faced failures in Phase 2 trials and will need to test higher doses in Phase 3. Recent collaborations and financial metrics have also been negative, contributing to a negative outlook for the company.

MPLT has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Buy based on their latest research and market trends.

According to 11 analysts, MPLT has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.